Approval · Notice of Compliance 28830 · 2022
BRIVLERA: Notice of Compliance 28830
Issued August 26, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28830
- Date
- August 26, 2022
- Company
- Ucb Canada IncOakville, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of alternate manufacturing sites for drug substance and change in the manufacturing process of Brivaracetam.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BRIVLERA | Not yet assigned | — |
Medicinal ingredients
- BRIVARACETAM 10 MG per TAB
- BRIVARACETAM 25 MG per TAB
- BRIVARACETAM 50 MG per TAB
- BRIVARACETAM 75 MG per TAB
- BRIVARACETAM 100 MG per TAB
- BRIVARACETAM 10 MG per ML